ACETO Subsidiary, Rising Pharmaceuticals, to Launch First Generic Version of Gris-PEG(R)

ACETO Subsidiary, Rising Pharmaceuticals, to Launch First Generic Version of
Gris-PEG(R)

PORT WASHINGTON, N.Y., Nov. 19, 2012 (GLOBE NEWSWIRE) -- ACETO Corporation
(Nasdaq:ACET), a global leader in the marketing, sale and distribution of
products for Human Health, Pharmaceutical Ingredients and Performance
Chemicals, today announced that Rising Pharmaceuticals Inc., its finished
dosage form generics subsidiary, will launch the first generic version of the
125mg and 250mg strengths of Ultramicrosize Griseofulvin Tablets USP, an FDA
approved generic version of PEDiNOL Pharmacal, Inc.'s Gris-PEG®. According to
IMS Health data, U.S. market sales for Ultramicrosize Griseofulvin Tablets,
which is an antifungal antibiotic that fights infections caused by fungus,
were approximately $16.7 million for the twelve months ended June 30, 2012.

ABOUT ACETO

ACETO Corporation, incorporated in 1947, is a global leader in the marketing,
sale and distribution of products for Human Health (finished dosage form
generics and nutraceutical products), Pharmaceutical Ingredients
(pharmaceutical intermediates and active pharmaceutical ingredients) and
Performance Chemicals (specialty chemicals and agricultural protection
products).With business operations in nine countries, ACETO distributes over
1,100 chemical compounds used principally as finished products or raw
materials in the pharmaceutical, nutraceutical, agricultural, coatings and
industrial chemical industries.ACETO's global operations, including a staff
of 26 in China and 12 in India, are distinctive in the industry and enable its
worldwide sourcing and regulatory capabilities.

The ACETO Corporation logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=13058

This news release contains forward-looking statements as that term is defined
in the federal securities laws. To the extent any statements made in this news
release contain information that is not historical, these statements are
essentially forward-looking and as such, are subject to known and unknown
risks, uncertainties and contingencies, many of which are beyond the control
of the Company, which could cause actual results and outcomes to differ
materially from those expressed herein. Factors that could cause actual
results to differ materially from those set forth or implied by any
forward-looking statement include, but are not limited to, risks and
uncertainties discussed in ACETO's reports filed with the Securities and
Exchange Commission, including, but not limited to, ACETO's Annual Report or
Form 10-K for the fiscal year ended June 30, 2012 and other filings. Copies of
these filings are available at www.sec.gov. ACETO undertakes no obligation to
publicly update or revise any forward-looking statements, whether from new
information, future events or otherwise.

CONTACT: Investor Relations Contact:
         Amy Glynn
         The Ruth Group
         (646) 536-7023
         aglynn@theruthgroup.com

ACETO Corporation Logo
 
Press spacebar to pause and continue. Press esc to stop.